MALVERN, PA, March 29 /PRNewswire-FirstCall/ - Novavax, Inc., (Nasdaq:
NVAX) a specialty biopharmaceutical company, today announced that Dr. Rahul
Singhvi, Vice-President Pharmaceutical Development and Manufacturing
Operations, will be presenting at the Stephens Inc. 2005 Nanotechnology
Investors Conference on Tuesday, April 5, 2005. Dr. Singhvi will provide an
update on Novavax's novel micellar nanoparticle (MNP) technology and its
potential for broad application.
WHEN: Tuesday, April 5th, 2005 at 10:30 AM PST
WHERE: Ritz Carlton Hotel, 1401 South Oak Knoll Ave, Pasadena, California
HOW: The live broadcast of the presentation can be accessed through our
website at www.novavax.com. After the presentation date, the
webcast will be archived on our website for 90 days.
Rahul Singhvi, Sc.D.
Dr. Singhvi holds a Master and Doctorate of Science degree in Chemical
Engineering from MIT and a Master of Business Administration from the Wharton
School. Dr. Singhvi joined Novavax after 10 years experience with Merck & Co,
where he most recently served as a Director within the Merck Manufacturing
About Novavax Inc.
Novavax, Inc. is a specialty biopharmaceutical company engaged in the
research, development and commercialization of proprietary products focused on
drug delivery and vaccine development. Novavax sells, markets, and distributes
a line of women's health prescription pharmaceuticals through its specialty
sales force calling on obstetricians and gynecologists throughout the United
States including ESTRASORB(R), its topical emulsion for estrogen therapy.
Novavax's micellar nanoparticle technology involves the use of patented oil
and water nanoemulsions that it believes can be used as vehicles for the
topical delivery of a wide variety of drugs and other therapeutic products,
including hormones. In addition, Novavax conducts research and development on
preventative and therapeutic vaccines and proteins for a variety of infectious
diseases, including HIV, influenza, SARS and E-selectin tolerogen for the
prevention of stroke.
Statements made in this press release that state Novavax's or
management's intentions, hopes, beliefs, expectations, or predictions of the
future are forward-looking statements. Forward-looking statements include but
are not limited to statements regarding product sales, future product
development and related clinical trials and statements regarding future
research and development. Novavax's actual results could differ materially
from those projected in such forward-looking statements. Factors that could
cause actual results to differ materially from those in the forward-looking
statements include, among other things, the following: general economic and
business conditions; competition; unexpected changes in technologies and
technological advances; ability to commercialize and manufacture products;
results of clinical studies; research and development activities; changes in,
or failure to comply with, governmental regulations; and the ability to obtain
adequate financing in the future. Additional information is contained in
Novavax's annual report on Form 10K for the year ended December 31, 2004
incorporated herein by reference. Statements made herein should be read in
conjunction with Novavax's Form 10K. Copies of the filing may be obtained by
contacting Novavax at 508 Lapp Road, Malvern, PA 19355 Tel 484-913-1200 or the
SEC at www.sec.gov.
SOURCE Novavax Inc.